The ADHD medication Vyvanse is facing impending supply issues due to manufacturing delays and increased demand, according to its manufacturer, Takeda Pharmaceuticals.
In a statement on the Vyvanse website, Takeda said the delays will impact 40 milligram (mg), 60 mg, and 70 mg Vyvanse tablets. The 40 mg tablets are in short supply now, but will likely be replenished in a few weeks, according to the statement. The company expects supplies of the 60 mg and 70 mg tablets to dip beginning in late June or early July, and said the shortage could last through September.
The pharmacy chains impacted include Walgreens, CVS, and Rite Aid.
RELATED: What Not to Say to Someone With ADHD
A representative from Takeda attributes increased demand for Vyvanse to shortages of other ADHD medications, including Adderall. This impacted the wholesalers and distributors, who usually have an extra supply on hand in case of such a shortage.
The FDA first announced the ongoing Adderall shortage in October 2022. Manufacturing delays at Teva Pharmaceuticals, one of the producers of amphetamine mixed salts (the active ingredient in Adderall), have forced patients to look for alternatives to the drug. One alternative has been Vyvanse, which does not contain amphetamine mixed salts.
In its statement, Takeda advised contacting your healthcare provider if you need an alternative to Vyvanse.
